Posted by Michael Wonder on 04 Nov 2022
Iveric Bio announces submission of first part of NDA for rolling review of avacincaptad pegol for the treatment of geographic atrophy
3 November 2022 - IVERIC bio today announced that it has submitted to the US FDA the first part of its new drug application for rolling review of avacincaptad pegol (Zimura) a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy secondary to age-related macular degeneration.
As previously announced, the Company received fast track designation from the FDA for avacincaptad pegol.
